CiC 2017: Crick Idea to Innovation (i2i)
Lead Research Organisation:
The Francis Crick Institute
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
People |
ORCID iD |
Publications
Wershof E
(2021)
A FIJI macro for quantifying pattern in extracellular matrix.
in Life science alliance
Wu Y
(2022)
A local human Vd1 T cell population is associated with survival in nonsmall-cell lung cancer.
in Nature cancer
Tan MSY
(2021)
Autocatalytic activation of a malarial egress protease is druggable and requires a protein cofactor.
in The EMBO journal
Wang VM
(2019)
CD9 identifies pancreatic cancer stem cells and modulates glutamine metabolism to fuel tumour growth.
in Nature cell biology
Demichev V
(2020)
DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput.
in Nature methods
Gomes AL
(2021)
Dynamic contrast-enhanced magnetic resonance imaging quantification of leukemia-induced changes in bone marrow vascular function.
in Haematologica
Wamaitha SE
(2020)
IGF1-mediated human embryonic stem cell self-renewal recapitulates the embryonic niche.
in Nature communications
Litchfield K
(2021)
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition.
in Cell
Virdi GS
(2022)
Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson's disease in midbrain dopaminergic neurons.
in NPJ Parkinson's disease
Riou C
(2022)
Rapid, simplified whole blood-based multiparameter assay to quantify and phenotype SARS-CoV-2-specific T-cells.
in The European respiratory journal
| Description | Creating a Pipeline for Expanded Access to Volumetric Visual Proteomics |
| Amount | £2,700,000 (GBP) |
| Organisation | Chan Zuckerberg Initiative |
| Sector | Private |
| Country | United States |
| Start | 09/2021 |
| Description | LifeArc Crick Fund - Pre-emptive stratification of patients for inclusion in metabolic clinicals using ultra-fast plasma proteome technology and machine learning |
| Amount | £339,114 (GBP) |
| Organisation | LifeArc |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2020 |
| End | 01/2022 |
| Description | LifeArc Crick Fund - iGUIDE technologies |
| Amount | £200,041 (GBP) |
| Organisation | LifeArc |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2020 |
| End | 07/2021 |
| Description | LifeArc- Crick fund - Generation and in vitro validation of specific therapeutic antibody candidates for treatment of pancreatic ductal adenocarcinoma |
| Amount | £296,000 (GBP) |
| Organisation | LifeArc |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2019 |
| End | 11/2021 |
| Description | LifeArc-Crick fund - Patani: Targeting harmful reactive transformation of astrocytes in neurodegeneration by restoring homeostatic intron retention |
| Amount | £311,904 (GBP) |
| Organisation | LifeArc |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2022 |
| End | 02/2024 |
| Description | LifeArc-Crick fund - Resolving the earliest therapeutically targetable molecular events in ALS |
| Amount | £386,024 (GBP) |
| Organisation | LifeArc |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2020 |
| End | 03/2022 |
| Description | MedTech SuperConnector - Ana Gomes |
| Amount | £76,000 (GBP) |
| Organisation | MedTech SuperConnector |
| Sector | Private |
| Country | United Kingdom |
| Start | 11/2019 |
| End | 07/2020 |
| Description | Targeting specific RAS isoforms using small molecule and PROTAC |
| Amount | £28,600 (GBP) |
| Organisation | Francis Crick Institute |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 04/2021 |
| End | 04/2022 |
| Description | Early clinical study with Barts Hospital looking at the use of MRI as a prognostic tool for leukaemia |
| Organisation | Barts Health NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Establishment of a MRI-based approach to evaluate the bone marrow vascular functionality as prognostic biomarker in acute myeloid leukemia |
| Collaborator Contribution | Expertise of two consultants and MRI time. |
| Impact | Early clinical study |
| Start Year | 2018 |
| Description | Jernej Ule - Automated magnetic rack to facilitate quick and efficient magnetic particle purification |
| Organisation | Gilson |
| Country | United States |
| Sector | Private |
| PI Contribution | Development of automated magnetic rack to facilitate quick and efficient magnetic particle purification |
| Collaborator Contribution | Advice on automated magnetic rack to facilitate quick and efficient magnetic particle purification |
| Impact | Crick funding for 20 days staff time. Prototype is being beta-tested at the Crick. |
| Start Year | 2018 |
| Description | Large volume 3D super-resolution microscopy |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Build an automated high-throughput super-resolution system by integrating electron microscopy (EM) sample preparation methods with automated easySTORM super-resolution microscopy of sample section arrays for 3D super-resolution imaging of cells and tissues. |
| Collaborator Contribution | High throughput super-resolved imaging |
| Impact | The project has so far proved that the concept of multi-colour array tomography for super-resolution imaging of large volumes works; and a working prototype of the required hardware to perform this imaging has been constructed. |
| Start Year | 2018 |
| Description | Oncolytic vaccinia virus for ovarian cancer: identifying novel targets for combination therapies |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Development of idea and creation of recombinant. As a cell signalling-oriented laboratory, we have interest in exploring the molecular mechanisms behind any synthetic lethal relationship. Such insights will further underpin any advantageous combination therapy we hope to observe in mouse models. |
| Collaborator Contribution | Validation of a potential vaccinia virus recombinant using in vivo mouse model of ovarian cancer. |
| Impact | Our overall aim is to move successful combination therapies from our mouse models into the clinic. By collaborating with the team at Imperial, who are experienced at setting up and running clinical trials, this is a realistic ambition. Professor McNeish has an excellent reputation for progressing first into patient studies of oncolytic viruses. |
| Start Year | 2018 |
| Title | METHOD, SOLUTION AND KIT FOR PREPARING A TISSUE SAMPLE FOR 3D IMAGING |
| Description | The present invention relates to a solution for the preparation of a tissue sample for the purpose of three dimensional (3D) imaging. The invention also relates to methods and uses involving the solution. |
| IP Reference | WO2020099870 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2020 |
| Licensed | No |
| Impact | none |
| Title | TEST RECEPTACLE RACK |
| Description | A test receptacle (2) rack comprises apertures (6) for receiving test receptacles, each aperture having a first side and a second side opposite the first side; permanent magnets (4, M1-M6), and an (actuator 16) to impart relative motion between the permanent magnets and the apertures (6) to switch between a first configuration and a second configuration. For a given aperture (6): in one of the first configuration and the second configuration, one of the permanent magnets is positioned adjacent to the first side of the aperture, in the other of the first configuration and the second configuration, a different one of the permanent magnets is positioned adjacent to the second side of the aperture. This is useful for many lab experiments involving magnetic beads placed in receptacles. |
| IP Reference | CA3088335 |
| Protection | Patent application published |
| Year Protection Granted | 2019 |
| Licensed | Commercial In Confidence |
| Impact | In development |
| Title | TEST RECEPTACLE RACK |
| Description | A test receptacle (2) rack comprises apertures (6) for receiving test receptacles, each aperture having a first side and a second side opposite the first side; permanent magnets (4, M1-M6), and an (actuator 16) to impart relative motion between the permanent magnets and the apertures (6) to switch between a first configuration and a second configuration. For a given aperture (6): in one of the first configuration and the second configuration, one of the permanent magnets is positioned adjacent to the first side of the aperture, in the other of the first configuration and the second configuration, a different one of the permanent magnets is positioned adjacent to the second side of the aperture. This is useful for many lab experiments involving magnetic beads placed in receptacles. |
| IP Reference | US2020338565 |
| Protection | Patent application published |
| Year Protection Granted | 2020 |
| Licensed | No |
| Impact | Still in development |
| Title | THERAPY FOR HEART DISORDERS |
| Description | The present invention relates to a population of cells with an increased proportion of left ventricular cardiomyocytes, and uses thereof, for example in treatment of disorders of the left ventricle and use in screening for drugs which may be used to treat disorders of the left ventricle. |
| IP Reference | WO2020245612 |
| Protection | Patent application published |
| Year Protection Granted | 2020 |
| Licensed | No |
| Impact | Too early to describe impacts |